Biosimilars
Biosimilar Uptake Surges After Order Set Change at an Academic Center
Biosimilar utilization surged at UAMS after switching oncology order set defaults, improving adoption and cost ...
MAY 31, 2026
AXS26: Biosimilars Could Slash Specialty Drug Spend 20% by 2029
Biosimilars adoption could cut specialty drug spend 20% by 2029, driving formulary innovation, collaboration, and ...
MAY 5, 2026
Cardinal Report: Future Bright for Biosimilars
Biosimilars in oncology are set for major growth, with FDA streamlining approvals and new cost-saving opportunities ...
MAY 1, 2026
Biosimilar Uptake Surges After Order Set Change at Academic Infusion Center
Biosimilar adoption study shows switching default oncology order sets to formulary biosimilars greatly increased ...
MARCH 30, 2026
IQVIA Data Show Uneven Biosimilar Uptake Across Drug Classes
Biologic therapies show variable adoption as pricing and policy barriers slow consistent biosimilar growth.
FEBRUARY 19, 2026
Biosimilar Patient Experience a Focus at NASP 2025
Humira biosimilars: NASP 2025 experts share insights on patient transitions, pharmacist roles, and outcomes after ...
DECEMBER 14, 2025
Is Relief in Sight for Interchangeable Biosimilars?
Biologics policy updates aim to ease guidance and expand patient access to lower cost treatments nationwide.
DECEMBER 12, 2025
Yuflyma Approved for Pediatric HS and UV
The FDA granted Yuflyma expanded indications for adolescent hidradenitis suppurativa and pediatric uveitis.
OCTOBER 21, 2025
Basics and Benefits of Biosimilars: A Rheumatologist’s Take
Biosimilars can improve patient access and reduce healthcare costs, but understanding basic concepts about this ...
MAY 24, 2025
Trump Prescription Drug Order Puts Spotlight on Price Tensions for Biosimilars
President Trump issued an executive order aimed at lowering prescription drug prices.
APRIL 24, 2025
Pharmacists’ Key Role in The Management of Humira Biosimilars
The introduction of Humira biosimilars to the US market in 2023 brought significant changes for providers, ...
NOVEMBER 27, 2024
Operational Considerations for Onboarding New Biosimilars
With 41 biosimilar products launched for 11 branded reference products, and at least 10 more for six other ...
NOVEMBER 25, 2024
